CKD & Anaemia: Reduced Erythropoiesis, Chronic Inflammation, and Tissue Hypoxia
Anaemia of chronic kidney disease is a common and progressive complication of chronic kidney disease, characterised by reduced red blood cell production and impaired oxygen delivery to tissues. Unlike iron-deficiency anaemia, this condition reflects failure of the kidney’s endocrine function and chronic inflammatory disruption of erythropoiesis. Anaemia in CKD can result in haemoglobin declining early, symptoms are often disproportionate to laboratory values, and correction requires more than iron replacement alone.
What You Need to Know
Healthy kidneys produce erythropoietin, a hormone that stimulates red blood cell production in the bone marrow in response to tissue oxygen demand. In chronic kidney disease, progressive loss of functional renal tissue reduces erythropoietin synthesis, leading to impaired erythropoiesis and a gradual decline in haemoglobin concentration. This reduction in red cell production means that fewer oxygen-carrying cells are available to supply tissues, contributing to fatigue and reduced functional capacity.
Anaemia in CKD is multifactorial rather than purely hormonal. In addition to reduced erythropoietin, several interacting processes worsen red cell deficiency:
chronic inflammation suppresses bone marrow activity and alters iron handling
iron becomes less available for red blood cell production despite normal or increased body stores
uraemic toxins shorten red blood cell lifespan
nutritional deficiencies further limit erythropoiesis
Together, these mechanisms produce the characteristic normocytic, normochromic anaemia of CKD, which progressively worsens as kidney function declines and contributes significantly to cardiovascular strain, reduced exercise tolerance, and overall disease burden.
Beyond the Basics
Reduced erythropoietin production
Erythropoietin is produced by specialised fibroblast-like cells in the renal cortex that sense local oxygen tension within the kidney. Under normal conditions, falling oxygen delivery triggers these cells to release erythropoietin, stimulating the bone marrow to increase red blood cell production. In chronic kidney disease, progressive nephron loss and interstitial fibrosis destroy this oxygen-sensing environment and reduce the number of functioning erythropoietin-producing cells.
As a result, erythropoietin levels fall even when tissues are clearly hypoxic and oxygen demand is high. The bone marrow therefore receives an inadequate hormonal signal to increase erythropoiesis, explaining why anaemia develops despite sufficient iron and nutrient availability and why haemoglobin fails to recover without replacement of the missing hormone.
Bone marrow suppression and inflammatory inhibition
CKD is characterised by a persistent low-grade inflammatory state driven by uraemic toxins, oxidative stress, and immune dysregulation. Inflammatory cytokines such as interleukin-6 and tumour necrosis factor directly suppress bone marrow activity and interfere with erythroid precursor maturation. They also reduce the responsiveness of bone marrow cells to erythropoietin, further limiting red blood cell production.
This inflammatory environment explains why some patients remain anaemic despite receiving erythropoiesis-stimulating agents, a phenomenon known as erythropoietin resistance. Anaemia in CKD therefore reflects not only hormone deficiency but also impaired marrow responsiveness caused by systemic inflammation.
Iron dysregulation and functional iron deficiency
Iron is essential for haemoglobin synthesis, but its availability depends not just on total body stores, but on the ability to mobilise and deliver iron to the bone marrow. In CKD, levels of the iron-regulatory hormone hepcidin rise due to inflammation and reduced renal clearance. Hepcidin blocks intestinal iron absorption and traps iron within macrophages and storage sites, preventing it from reaching developing red blood cells.
As a result, patients may have normal or even elevated ferritin levels while still lacking usable iron for erythropoiesis. This functional iron deficiency further limits haemoglobin production and contributes to poor response to erythropoietin therapy unless iron availability is also addressed.
Reduced red blood cell survival
Red blood cells normally circulate for about 120 days, but in CKD this lifespan is significantly shortened. Uraemic toxins, oxidative stress, and abnormal plasma composition damage red blood cell membranes, making them more fragile and prone to premature destruction within the spleen and circulation.
This increased turnover places additional demand on the bone marrow to replace lost cells, yet erythropoietin deficiency, inflammation, and iron restriction prevent adequate compensation. The result is a persistent and progressive anaemia.
Tissue hypoxia and cardiovascular strain
As haemoglobin falls, oxygen delivery to tissues declines, forcing the heart to increase cardiac output in an attempt to maintain oxygen supply. Chronic anaemia therefore produces sustained tachycardia, increased myocardial workload, and left ventricular hypertrophy. Over time, this contributes to the development and progression of heart failure and increases the risk of arrhythmias and ischaemic events.
This interaction explains why anaemia in CKD is strongly associated with fatigue, reduced exercise tolerance, worsening cardiovascular disease, and increased mortality.
Progression with declining renal function
Anaemia often begins early in CKD, but progresses gradually as nephron loss and fibrosis worsen. Because this decline is slow, symptoms are frequently subtle and attributed to ageing or general ill health, delaying recognition and treatment.
By the time anaemia becomes clinically obvious, haemoglobin levels may already be significantly reduced and systemic effects well established, highlighting the importance of early monitoring and intervention in chronic kidney disease.
Clinical Connections
Anaemia of CKD typically presents with persistent fatigue, reduced exercise tolerance, dyspnoea on exertion, dizziness, and impaired concentration. Patients often describe feeling “washed out” or breathless with minimal activity, even when fluid status and lung function are stable. On examination, pallor, tachycardia, and orthostatic symptoms may be present, reflecting reduced oxygen-carrying capacity rather than volume depletion or primary cardiac disease.
In clinical practice, anaemia in CKD is identified through:
falling haemoglobin with normal red cell indices
low or inappropriately normal erythropoietin levels
evidence of iron restriction despite adequate ferritin
reduced response to erythropoiesis-stimulating agents in the presence of inflammation
Management targets the mechanisms driving anaemia. Erythropoiesis-stimulating agents are used to replace deficient erythropoietin, intravenous iron is often required to overcome hepcidin-mediated iron trapping, and underlying inflammation or blood loss must be addressed. Improving haemoglobin reduces cardiac workload, improves exercise capacity, and decreases heart failure progression, but aggressive correction increases the risk of hypertension, thrombosis, and stroke, making careful titration and ongoing monitoring essential in CKD care.
Concept Check
Why does reduced erythropoietin production lead to anaemia in CKD?
How does chronic inflammation impair erythropoiesis?
What is meant by functional iron deficiency in CKD?
Why does anaemia increase cardiovascular risk in chronic kidney disease?
Why may anaemia progress silently as renal function declines?